The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | IMMUNOPLANT: linvoseltamab immuno-consolidation to drive MRD negativity in newly diagnosed myeloma
Dickran Kazandjian, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, shares the encouraging results of the IMMUNOPLANT study (NCT06376526), a Phase II trial investigating the use of abbreviated fixed-duration linvoseltamab immuno-consolidation to deepen responses in patients with newly diagnosed multiple myeloma (MM) who are measurable residual disease (MRD) positive after initial combination therapy. Patients enrolled in the trial had been treated with standard triplet/quad-based combination therapy and attained a very good partial response (VGPR) or better, but remained MRD positive by clonoSEQ. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
